logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Southern african HIV clinicians society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update

Govender NP, Meintjes GA, Mangena PM, Nel J, Potgieter S,  et al.
2019-11-08 • Southern African Journal of HIV medicine
2019-11-08 • Southern African Journal of HIV medicine
Journal Article
|
Short Report

Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?

Cox HS, Hughes J, Black JM, Nicol MP
2018-03-13 • Lancet Infectious Diseases
2018-03-13 • Lancet Infectious Diseases
Treatment for drug-resistant tuberculosis is largely delivered through standardised, empirical combination regimens in low-resource, high-burden settings. However, individualised treatme...
Journal Article
|
Research

Time to embrace access programmes for medicines: Lessons from the South African flucytosine access programme

Shroufi A, Govender NP, Meintjes GA, Black JM, Nel J,  et al.
2020-06-01 • International Journal of Infectious Diseases
2020-06-01 • International Journal of Infectious Diseases
BACKGROUND
Cryptococcal Meningitis (CM) is estimated to cause 181,000 deaths annually; with the majority occurring in Sub Saharan Africa. Flucytosine is recommended by the World Heal...
Journal Article
|
Research

Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study

Mashau RC, Meiring ST, Quan VC, Nel J, Greene GS,  et al.
2022-06-21 • Lancet Infectious Diseases
2022-06-21 • Lancet Infectious Diseases
BACKGROUND
Although flucytosine is a key component of WHO-recommended induction treatment for HIV-associated cryptococcal meningitis, this antifungal agent is not widely available in...